- Home
- JSPR vs AVIR Comparison
JSPR vs AVIR Comparison
Compare JSPR & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JSPR
- AVIR
- Stock Information
- Founded
- JSPR 2018
- AVIR 2012
- Country
- JSPR United States
- AVIR United States
- Employees
- JSPR N/A
- AVIR N/A
- Industry
- JSPR Biotechnology: Biological Products (No Diagnostic Substances)
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- JSPR Health Care
- AVIR Health Care
- Exchange
- JSPR Nasdaq
- AVIR Nasdaq
- Market Cap
- JSPR 342.2M
- AVIR 284.6M
- IPO Year
- JSPR N/A
- AVIR 2020
- Fundamental
- Price
- JSPR $22.81
- AVIR $3.42
- Analyst Decision
- JSPR Strong Buy
- AVIR Hold
- Analyst Count
- JSPR 10
- AVIR 1
- Target Price
- JSPR $74.86
- AVIR $6.88
- AVG Volume (30 Days)
- JSPR 216.7K
- AVIR 188.7K
- Earning Date
- JSPR 11-07-2024
- AVIR 11-07-2024
- Dividend Yield
- JSPR N/A
- AVIR N/A
- EPS Growth
- JSPR N/A
- AVIR N/A
- EPS
- JSPR N/A
- AVIR N/A
- Revenue
- JSPR N/A
- AVIR N/A
- Revenue This Year
- JSPR N/A
- AVIR N/A
- Revenue Next Year
- JSPR N/A
- AVIR N/A
- P/E Ratio
- JSPR N/A
- AVIR N/A
- Revenue Growth
- JSPR N/A
- AVIR N/A
- 52 Week Low
- JSPR $4.00
- AVIR $2.88
- 52 Week High
- JSPR $31.01
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- JSPR 56.60
- AVIR 52.69
- Support Level
- JSPR $19.12
- AVIR $3.27
- Resistance Level
- JSPR $23.60
- AVIR $3.50
- Average True Range (ATR)
- JSPR 1.58
- AVIR 0.13
- MACD
- JSPR -0.02
- AVIR 0.02
- Stochastic Oscillator
- JSPR 60.00
- AVIR 71.43
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).